15.4亿美元!信诺维CLDN18.2 ADC授权安斯泰来

医药魔方Info
30 May

5月30日,信诺维和安斯泰来宣布,双方就XNW27011(一款靶向CLDN18.2,处于临床阶段的新一代抗体偶联药物)已达成一项独家许可协议,授予安斯泰来独家拥有XNW27011在全球(除中国大陆、香港、澳门和台湾地区外)开发和商业化的权利。根据协议条款,信诺维将获得1.3亿美元的首付款,并有资格收取最高7000万美元的近期付款,以及最高可达13.4亿美元的与开发、注册、商业化相关的里程碑付款。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10